Johnson & Johnson Earnings: New Blockbuster Drug Olysio Lifts Sales But May Face Competition Soon

Johnson & Johnson recently released its second quarter results. While the company beat consensus estimates, its stock fell slightly due to a weaker-than-expected outlook for the second half of 2014. This can be attributed to the competition that its new blockbuster drug Olysio is likely to face going forward, as well as the impact of divestiture of Ortho-Clinical Diagnostics. Nevertheless, the broader story remained the same. Pharmaceutical business grew stronger driven both by the ramp up of He...